tHEORetically Speaking
Menu Close
  • Home
  • Guest Authors
  • About Us
  • HealthEconomics.Com
  • HE Jobs Portal

AMNOG

0

AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?

Posted on July 1, 2022 by Undine McEvoy

What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price… Continue Reading →

podcast, podcasts, Uncategorized AMNOG, biopharma, German market access, Market Access
0

Prof. Dr. Juergen Wasem – What happens, when negotiations fail?

Posted on December 15, 2021 by Undine McEvoy

Who could be better to tell us the real insights, how the arbitration board works than Prof. Dr. Juergen Wasem, the former head of the AMNOG arbitration board and the current head of the DiGA arbitration board. In this wide ranging conversation Dr. Stefan… Continue Reading →

podcast, podcasts AMNOG, Market Access, pharmaceutical reimbursement
0

Bibiane Schulte-Bosse – How to fight well in AMNOG negotiations.

Posted on November 1, 2021 by Undine McEvoy

In this Podcast episode, Dr. Stefan Walzer is explaining the details of the price negotiations within the AMNOG process together with negotiating expert and lawyer  Bibiane Schulte-Bosse. Get into the hot areas of AMNOG – the negotiations and let us… Continue Reading →

podcast, podcasts AMNOG, Market Access, pharma pricing, pharmaceutical reimbursement
0

Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??

Posted on October 1, 2021 by Undine McEvoy

In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement specifics including the famous article 71, which allows an early paid access. Who else could better speak about the Swiss system with… Continue Reading →

podcast, podcasts AMNOG, HEOR, Market Access, pharmaceutical reimbursement, Swiss market access
0

Dr. Mathias Flume – AMNOG will change in 2022, but how?

Posted on September 1, 2021 by Undine McEvoy

In this Podcast episode, Dr. Stefan Walzer is talking with Dr. Mathias Flume about the AMNOG process as well as interesting details about the market access process in Germany. Mathias is a core stakeholder within the regional payer system in… Continue Reading →

podcast, podcasts AMNOG, HEOR, Market Access

About the HealthEconomics.Com Blog:

Insights, observations, executive interviews, critical analysis, and new research for health economics, outcomes research, real-world evidence, and market access community. We welcome guest bloggers.

Check your inbox or spam folder to confirm your subscription.

Recent Posts

  • The Emerging Outcomes Demonstration / Cost Management Challenge
  • Hard to Define, Harder to Find Patients: Using AI & Real-World Data to Understand Treatment Resistant Depression
  • Get to Know R-S-S (Regulatory Scientific and Health Solutions)
  • Will 2023 Be the Year AI Disrupts Healthcare?

HealthEconomics.Com Twitter Feed

HealthEconomics.Com | A Scientist.com Company Follow

www_healthecon
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
24 Mar

AMCP 2023 Panel Argues for Patient-Centered Prior Authorization

http://ow.ly/RZ4050NrAhI

#HEOR #Payers #PatientCentered #Healthcare

Reply on Twitter 1639379097456607233 Retweet on Twitter 1639379097456607233 Like on Twitter 1639379097456607233 1 Twitter 1639379097456607233
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
24 Mar

NICE Recommends Novel Gene Therapy for Rare Genetic Brain Disorder

http://ow.ly/1wIc50NrzLB

#HEOR #RareDisease #OrphanDrug #Therapeutics #GeneTherapy

Reply on Twitter 1639364008468951040 Retweet on Twitter 1639364008468951040 Like on Twitter 1639364008468951040 Twitter 1639364008468951040
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
24 Mar

Patient Advocacy Groups Decry NIH Refusing to Exert March-In Rights for Prostate Cancer Drug Xtandi

http://ow.ly/mWTS50Nry5X

#HEOR #DrugPrices #Patents #Therapeutics #Pharma

Reply on Twitter 1639348911264636929 Retweet on Twitter 1639348911264636929 Like on Twitter 1639348911264636929 Twitter 1639348911264636929
Load More...

Archives

Visit our website, HealthEconomics.Com, top ranked by Google for news, jobs and resources in healthcare value, market access and more. Read our privacy policy here.
© 2023 tHEORetically Speaking. All rights reserved.
Hiero by aThemes